PF-05212384 (PKI-587) for t-AML/MDS or de Novo Relapsed or Refractory Acute Myeloid Leukemia (AML) (LAM-PIK) (5)
Phase II Evaluating the Efficacy of the Dual Inhibition of Phosphoinositide 3 Kinase (PI3K)/Akt /Mammalian Target Of Rapamycine (mTOR) Signaling Pathway by PF-05212384 (PKI-587) for Patients With Myeloid Neoplasm Secondary to Chemo-radiotherapy (t-AML/MDS) or de Novo Relapsed or Refractory AML.
Sponsor: Fondation ARC
Terminated
No objective response was observed at the first step. The treatment was considered ineffective, with a complete clinical trial suspension.
Other terminated trials from Fondation ARC
A PHASE2 clinical study on Acute Myeloid Leukemia, in Relapse and Therapy-related Acute Myeloid Leukemia and Myelodysplastic Syndrome, this trial is terminated or withdrawn. The trial is conducted by Fondation ARC and has accumulated 11 data snapshots since 2015. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
11 versions recorded-
Oct 2025 — Present [monthly]
Terminated PHASE2
-
Sep 2024 — Oct 2025 [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Dec 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Dec 2021 [monthly]
Terminated PHASE2
▶ Show 6 earlier versions
-
Nov 2020 — Jan 2021 [monthly]
Terminated PHASE2
-
Mar 2019 — Nov 2020 [monthly]
Terminated PHASE2
Status: Active Not Recruiting → Terminated
-
Jun 2018 — Mar 2019 [monthly]
Active Not Recruiting PHASE2
-
Sep 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE2
-
Feb 2017 — Sep 2017 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE2
First recorded
Aug 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Fondation ARC
- Institut Curie
- National Cancer Institute, France
For direct contact, visit the study record on ClinicalTrials.gov .